Systemic treatment for hereditary cancers: a 2012 update.

about

Cytotoxic and targeted therapy for hereditary cancers Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.The changing landscape of hereditary cancer genetic testing.

P2860

Q26739366-66154C0D-0CFD-4C16-9319-F71C9C357F0E Q38389226-4359C0F2-0009-45DC-B2A5-5BA1B2927A16 Q48369392-6EA994CC-42F3-41AA-8FF9-EFDEA8139F90

P2860

Systemic treatment for hereditary cancers: a 2012 update.

Item

http://www.wikidata.org/entity/Q36755366

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Systemic treatment for hereditary cancers: a 2012 update.

@ast

Systemic treatment for hereditary cancers: a 2012 update.

@en

type

Item

label

Systemic treatment for hereditary cancers: a 2012 update.

@ast

Systemic treatment for hereditary cancers: a 2012 update.

@en

prefLabel

Systemic treatment for hereditary cancers: a 2012 update.

@ast

Systemic treatment for hereditary cancers: a 2012 update.

@en

P1476

Systemic treatment for hereditary cancers: a 2012 update.

@en

P2093

Evgeny N Imyanitov

http://www.w3.org/2001/XMLSchema#string

P2860

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Microsatellite instability in colorectal cancer-the stable evidence.

An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions

P2888

1897-4287-11-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1897-4287-11-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tomasz Byrski

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236099236

http://www.w3.org/2001/XMLSchema#string

P6179

1032139569

http://www.w3.org/2001/XMLSchema#string

P698

23548133

http://www.w3.org/2001/XMLSchema#string

P932

3622547

http://www.w3.org/2001/XMLSchema#string

Systemic treatment for hereditary cancers: a 2012 update.

about

P2860

P2860

Systemic treatment for hereditary cancers: a 2012 update.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932